myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.

Information gained from our advanced engineered tissue models can assist drug developers in defining safe and effective doses for first in human studies. Reduction in attrition rate and acceleration of clinical translation of the most promising therapeutic candidates to address pressing unmet medical needs is what we strive for.

SERVICES

Click below to learn more about the myriamed platform portfolio.

MYR- 6 values

Ownership

We have a strong academic and entrepreneurial background. It is our passion to enable our customers to address unmet medical needs quickly, safely, efficiently, and cost-effectively.

Innovation

We constantly innovate our technology platforms. We respect freedom of ideas and combine both internal and external technology and expertise from around the world to find best solutions.

Communications

We welcome diverse opinions and adverse views presented in a constructive manner. We strive to openly, fairly, and clearly communicate the rationale for our decisions.

Trust

We believe in trusting people internally and externally to quickly deliver solutions to complex system issues. Trust is enhanced by reliability, quality, and honesty.

Success

We value success achieved under high ethical standards and environmental consciousness over success gained at the expense of others. We strive to be responsive to changes in technology and science impacting the needs of our customers.

Financial goal

is healthy and sustainable growth. The long-term prospect of success always lies at the heart of our strategies.

NEWS

by Christian Vitt 0
2024-07-02 18:36
by Christian Vitt
(comments: 0)

myriamed and SYNENTEC are proud to unveil the myrImager - a groundbreaking platform for high-content-analysis of pluripotent stem cell-derived heart muscle, skeletal muscle and connective tissue.

2024-07-02 18:36
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2023-10-09 11:54
by Christian Vitt
(comments: 0)

Can hearts and heart muscle be repaired? What role do pluripotent stem cells play in this? And how could the same technology also produce artificial flesh on a massive scale?

2023-10-09 11:54
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2023-09-27 10:01
by Christian Vitt
(comments: 0)

At the SPS Meeting Developer Tim Meyer of the myriamed GmbH presents a preview of its brand new MyrImager!

2023-09-27 10:01
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2023-06-20 16:16
by Christian Vitt
(comments: 0)

…and 3D organoids offer potential solutions to some of these challenges. Here are a few key challenges and how 3D organoids can help address them.

2023-06-20 16:16
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2023-04-11 13:15
by Christian Vitt
(comments: 0)

Because the myriamed services and 3D Organoids are well known for a better and faster drug development. Let´s talk about the facts…

2023-04-11 13:15
by Christian Vitt
(comments: 0)
by Christian Vitt 0
2022-12-01 10:41
by Christian Vitt
(comments: 0)

Parliamentary State Secretary Dr. Nick awards 41st Animal Welfare Research Prize – this year's award goes to scientists from Hannover and Göttingen.

2022-12-01 10:41
by Christian Vitt
(comments: 0)

„E Pluribus Unum (out of many - one)“

Separating the pharmacological wheat from the chaff to enhance safety and efficacy of new molecular entities (NMEs) is the primary goal of myriamed. Our unique strengths are high quality secondary screens based on proprietary tissue engineered organ platforms. We offer our support to the pharmaceutical and biotech industry at an early stage of drug development to improve the attrition rate and enhance cost-effectiveness of drug development.

Get in touch with our team!

Dr. Eriona Heta

Research & Development specialist with many years of experience in cardiac tissue engineering, myriamed platforms and genetic engineering. Dr. Heta obtained her PhD in Molecular Medicine at the University Medical Center Göttingen and has extensive knowledge in strategic management.

Get in contact

Gunther Zimmermann

Managing Director

Results driven general manager with more than 20 years of experience in personnel and financial matters. In addition to his role at myriamed he is Managing Director at Tissue Systems Holding, procurist at Jobactive and Executive Partner at Hanfried Personaldienstleistungen.

Get in contact

Dr. Uwe Carl

Director Technical Operations

With more than 25 years of experience in the life science environment he has accumulated extensive skills in building up and structuring R&D and production facilities. Before joining myriamed he served for almost 20 years in various roles at IBA Lifesciences.

Get in contact

Copyright 2024 Seaside Media. All Rights Reserved.